We value your privacy
If you'd prefer that cookies weren't placed on your computer when you visit our site, you can use the controls below to allow or disallow different types of cookie. Some cookies are essential for the website to work, so they can't be disallowed.
These cookies give us anonymised information on how people use our website. We use these cookies to help us tailor our site to meet the needs of our visitors, for example by making sure our most popular pages are easy to find.
These cookies serve a number of purposes, such as allowing you to share our content with your friends and social networks. We also use these cookies to provide targeted advertising, so you may see relevant adverts based on the pages you look at on our website.
Legal Experts Welcome New Breathalyser To Help Tackle Asbestos-Related Cancer
The Breath Biopsy Is Being Trialled Over The Next Three Years
Specialist lawyers at Irwin Mitchell have welcomed the trial of a new breathalyser designed to help with the early detection of an asbestos-related cancer.
The Breath Biopsy has been devised by Owlstone Medical in Cambridge which has partnered with a major building trade union in North America to analyse chemicals found on the breath of people with historical exposure to asbestos and those with confirmed mesothelioma – a terminal cancer of the lining of the lungs most commonly associated with being exposed to the hazardous dust and fibres.
Asbestos-related disease lawyers at national legal firm Irwin Mitchell witness the effects of mesothelioma on a daily basis and have praised this latest development in research, with the project divided into two phases and expected to run for three years.
“The trialling of this new device is a hugely exciting prospect for mesothelioma researchers, and those suffering from the disease should be made aware that research is advancing.
Through our work in assisting mesothelioma victims and their families, we see the damage and upset caused by the cancer. We hope that this breathalyser will help with early diagnosis and possibly lead to further medical developments.”
Rosemary Giles - Partner